Dr. David R. Greeley, MD
Neurology (Neurology Physician)
1520 W 3rd Ave Ste 101
Spokane, WA 99201
Who else practices at this address →
Spokane County includes primary care (67% of residents) and dental (43% of residents) and mental health (29% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Washington School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 455
Licensed in Washington since 1993, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Washington School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
WA license MD00030536 (first issued 1993; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 455
- Services billed
- 46,484
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 26,600 | 45 |
| Injection, incobotulinumtoxin a, 1 unit | 12,245 | 27 |
| Established patient office or other outpatient visit, 30-39 minutes | 723 | 362 |
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 643 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 141 | 82 |
| New patient office or other outpatient visit, 45-59 minutes | 133 | 133 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 100 | 40 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 78 | 25 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 74 | 26 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 52 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Spokane, WA | 180 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Spokane, WA | 169 |
| Memantine Hcl Other prescribers in Spokane, WA | 58 |
| Rasagiline Mesylate | 51 |
| Primidone Other prescribers in Spokane, WA | 38 |
| Nurtec Odt (rimegepant sulfate) Other prescribers in Spokane, WA | 35 |
| Quetiapine Fumarate Other prescribers in Spokane, WA | 35 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Spokane, WA | 34 |
| Gabapentin Other prescribers in Spokane, WA | 32 |
| Clonazepam Other prescribers in Spokane, WA | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 136 payments worth $5,081 in total to this clinician.
| Ipsen Innovation | $1,668 |
|---|---|
| AbbVie Inc. | $621 |
| Eisai Inc. | $447 |
| Merz Pharmaceuticals, LLC | $307 |
| Teva Pharmaceuticals USA, Inc. | $292 |
| Lundbeck LLC | $276 |
| Lilly USA, LLC | $271 |
| Neurocrine Biosciences, Inc. | $168 |
| Food and Beverage | $3,821 |
|---|---|
| Travel and Lodging | $1,260 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Innovation Apr 24, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $653 |
| Ipsen Innovation Apr 25, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $556 |
| Ipsen Innovation May 12, 2025 | Travel and Lodging travel to Miami, FL · in-kind | $51.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $19,386 in research payments for these studies, mostly to the institutions running them.
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
Ipsen Innovation · Recruiting · NCT06937931 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.